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1 |  INTRODUCTION
Thin melanomas measuring 1  mm or less account for ap-
proximately 50% of all melanomas diagnosed in our area.1 
Although thin melanomas have a good prognosis, the abso-
lute number of deaths is very high due to the sheer number 
of cases.2
Before the 8th edition of the American Joint Committee 
on Cancer (AJCC) Cancer Staging Manual,3 most clini-
cal guidelines recommended sentinel lymph node biopsy 
(SLNB) for patients with thin melanoma and additional 
risk factors, such as tumor thickness ≥0.75 mm, ulceration, 
mitosis, and a high Clark level.4 The decision to perform 
SLNB in patients with melanoma ≤1 mm should be made 
by weighing the likelihood of detecting SLN metastasis, 
established as an expected rate of at least 5%,5 against the 
potential complications, not to mention cost, of the pro-
cedure.6 A recent systematic review and meta‐analysis es-
tablished that the presence of at least one mitosis was the 
most important predictor of SLN metastasis with respect 
to adjusted variables in patients with thin melanoma.7 
However, in the new edition of the AJCC Cancer Staging 
Manual,3 mitotic rate is no longer considered a staging 
criterion for thin melanoma, although its prognostic value 
is still clearly recognized. The only two updated clini-
cal practice guidelines—version 1.2018 of the National 
Comprehensive Cancer Network (NCCN) guidelines 
(version 1.2018)8 and the American Society of Clinical 
Oncology‐Society of Surgical Oncology (ASCO‐SSO) 
guideline9—recommend discussing and considering SLNB 
in patients with T1b melanoma (ulcerated tumors or tumors 
with a Breslow thickness ≥0.8 mm). The NCCN guidelines 
additionally recommend considering SLNB in patients 
with T1a melanoma (tumors <0.8 mm without ulceration) 
when  ≥2  mitoses/mm2 are observed, especially in young 
patients or patients with lymphovascular invasion.
The main objective of this study was to identify prognos-
tic factors for thin melanoma and predictive factors associ-
ated with SLN involvement in a large multicenter cohort of 
patients with melanoma.
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Abstract
Mitotic rate is no longer considered a staging criterion for thin melanoma in the 
8th edition of the American Joint Committee on Cancer Staging Manual. The aim 
of this observational study was to identify prognostic factors for thin melanoma 
and predictors and prognostic significance of sentinel lymph node (SLN) involve-
ment in a large multicenter cohort of patients with melanoma from nine tertiary 
care hospitals. A total of 4249 consecutive patients with thin melanoma diagnosed 
from January 1, 1998 to December 31, 2016 were included. The main outcomes 
were disease‐free interval and melanoma‐specific survival for the overall popula-
tion and predictors of SLN metastasis (n = 1083). Associations between survival 
and SLN status and different clinical and pathologic variables (sex, age, tumor 
location, mitosis, ulceration, regression, lymphovascular invasion, histologic 
subtype, Clark level, and Breslow thickness) were analyzed by Cox proportional 
hazards regression and logistic regression. SLN status was the most important 
prognostic factor for melanoma‐specific survival (hazard ratio, 13.8; 95% CI, 
6.1‐31.2; P < 0.001), followed by sex, ulceration, and Clark level for patients who 
underwent SLNB. A mitotic rate of >2 mitoses/mm2 was the only factor associ-
ated with a positive SLN biopsy (odds ratio, 2.9; 95% CI, 1.22‐7; P = 0.01. SLN 
status is the most important prognostic factor in thin melanoma. A high mitotic 
rate is associated with metastatic SLN involvement. SLN biopsy should be dis-
cussed and recommended in patients with thin melanoma and a high mitotic rate.
K E Y W O R D S
age factors, Cox proportional hazards regression analysis, melanoma, mitotic index, multiple imputation, 
neoplasia staging, prognostic factors, sentinel lymph node biopsy, survival
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2 |  MATERIALS AND METHODS
We designed a multicenter observational study based on 
the Strengthening the Reporting of Observational Studies in 
Epidemiology guidelines.10 Patients were recruited in nine 
hospitals that formed part of the Sentinel Lymph Node Study 
Group in Melanoma (SENTIMEL). Patients with melanoma 
were selected from the databases of seven Spanish hospi-
tals (Instituto Valenciano de Oncología [IVO] in Valencia, 
Hospital Universitario de Salamanca [HUS] in Salamanca, 
Hospital La Fe [HLF] in Valencia, Hospital Virgen Macarena 
[HVM] in Seville, Hospital de la Coruña [HC] in A Coruña, 
Hospital German Trials i Pujol [HGT] in Badalona, and 
Hospital Clìnic [HC] in Barcelona) and two hospitals outside 
Spain (Hopital de Coimbra [HCo] in Portugal and Hospital 
de Turin [HT] in Italy). All the hospitals are tertiary care hos-
pitals and reference centers for melanoma. Patients registered 
in any of the databases up to December 31, 2016 were in-
cluded in the study. Patients diagnosed after January 1, 1998 
were included. Those treated before this date were intention-
ally omitted, as most of the hospitals did not start performing 
SLNB in patients considered at risk for regional lymphatic 
metastasis until 1998.3 All the databases complied with the 
relevant laws. The study was approved by the institutional re-
view board of Hospital Universitario Reina Sofía in Córdoba 
(Spain) which acted as a reference committee.
2.1 | Inclusion criteria and case definition
All patients ≥18 years old with a solitary localized melanoma, 
without evidence of metastasis at diagnosis with a thickness of 
1 mm or less were analyzed, regardless of whether or not they 
had undergone SLNB. They had been included consecutively 
and prospectively in the relevant databases. SLNB was per-
formed in a similar way in all centers and used any combina-
tion of vital blue dye, radioactive dye, radioactive colloid and 
preoperative lymphoscintigraphy for location SLN. The sur-
gical management of primary melanoma was performed with 
a 1 cm wide excision, as recommended by most guidelines.
Pathologic examination of the sentinel lymph nodes at 
each hospital was performed using standard procedures that 
have previously been described.11 The HCUB has been ap-
plying the Minitub protocol (EORTC 1208: Minitub registra-
tion study) since 2011.
2.2 | Independent variables
Drawing on the literature and the available evidence, the fol-
lowing clinical and pathologic variables were chosen as in-
dependent variables:
Clinical characteristics: sex, age (continuous variable clas-
sified as <40, 40‐65, and >65 years), and anatomic location 
(head/neck, trunk, upper extremities, or lower extremities).
Histologic characteristics: Breslow thickness, mitotic rate, 
ulceration, regression, lymphovascular invasion, Clark level, 
and histologic subtype. For thickness, patients were reclassi-
fied according to the new AJCC staging criteria (<0.8 mm 
vs ≥0.8 mm). Thickness was rounded to the nearest decimal 
point (0.1 mm), as recommended by the AJCC.3 Mitotic rate 
(number of mitoses/mm2) was evaluated using the hot spot 
method, which consists of identifying the area of the dermis 
with the highest number of mitotic figures and counting the 
mitoses in adjacent fields until an area of 1 mm2 is reached. 
The previously established cutoffs of 0, 1, 2, and >2 mitoses/
mm2 were used.12 Ulceration, regression, and lymphovascu-
lar invasion were evaluated as presence or absence and Clark 
level was divided into levels II‐III vs IV‐V.
The type of recurrence was recorded (locoregional, re-
gional or distant recurrence).
2.3 | Outcomes
The primary outcome measures for the overall population 
were disease‐free interval (DFI) and melanoma‐specific sur-
vival (MSS). Survival was measured from time of primary 
tumor excision to time of local, regional lymphatic, or dis-
tant recurrence or death due to melanoma (respective events 
for DFI and MSS), or to time of last follow‐up or death due 
to a cause other than melanoma (whichever happened first). 
National death records were used by some hospitals to evalu-
ate the vital status in patients.
2.4 | Statistical analysis
Difference between SLN status and variables was investi-
gated with chi‐square test. Survival curves were built using 
the Kaplan‐Meier method and compared using the log rank 
test. Cox proportional hazards regression analysis was used 
for the multivariate analysis including and the assumption 
of proportionality was evaluated graphically using a log‐log 
graph. Missing values were imputed using multiple imputa-
tion, for which 10 full datasets were created. The estimates 
were combined using Rubin's rules.13 Before running the 
model, SPSS's missing value add‐on module was used to 
check whether the missing data were missing at random. The 
variables that have been imputed were age, sex, anatomic lo-
cation, mitotic rate, ulceration histologic, subtype, lympho-
vascular invasion, regression and Clark level, with different 
levels of missingness. And variables without missing values 
were used to impute and recreate the scenario of values under 
missing at random assumption (MAR).
The dependent variable for patients who underwent SLNB 
was a positive result. Binomial logistic regression analysis 
was used to evaluate the effects of the independent variables 
on the likelihood of SLN positivity, using variables potentially 
associated with SLN status in the univariate model (P < 0.2) 
4238 |   TEJERA‐VAQUERIZO ET Al.
for the multivariate model with a backward stepwise elimi-
nation and multivariate analysis of Cox proportional hazards 
models were performed after multiple imputation and were 
adjusted for all the study variables: age, sex, anatomic loca-
tion, Breslow thickness, ulceration, mitotic rate, histologic 
subtype, Clark level, lymphovascular invasion, and regres-
sion. The variable hospital was not included in the binomial 
logistic regression model to avoid oversaturation.
Statistical significance was set at a P value of less than 
0.05. All statistical analyses were performed in SSPS 20.0 
(Illinois, Inc; USA).
3 |  RESULTS
We analyzed data for 4249 patients with thin melanoma 
(≤1 mm); of this entire cohort, 1897 patients were men (44.6%) 
and 2352 were women (55.4%). The median age was 57.8 years 
(interquartile range, 40‐66 years). The most common age for 
diagnosis was 41‐65  years (48.1%) and the most common 
anatomic location was the trunk (42.4%). Absence of mitosis 
was the most common finding (67%) and superficial spreading 
melanoma was the most common histologic subtype. A tumor 
thickness of <0.8 mm was reported for 71% of patients. The 
characteristics of the population are summarized in Table 1.
After a median follow‐up of 68  months, 158 patients 
(3.7%) experienced disease recurrence (locoregional 22.9%, 
regional 34.6%, and distant 42.5%) and 77 (1.8%) died of 
melanoma (uncensored in the survival analysis).
For the overall population (n = 4249), sex, Breslow thick-
ness, ulceration, Clark level, and histologic subtype were all 
T A B L E  1  Characteristics of 4249 patients with thin melanoma 
according to the 8th edition of the American Joint Committee on 
Cancer Staging Manual
Characteristic No. %
Sex
Male 1897 44.6
Female 2352 55.4
Age of diagnosis
Median 57.8
p75‐p25 40‐66
≤40 y old 1120 26.5
41‐65 y old 2034 48.1
>65 y old 1071 25.3
Anatomic location (missing = 133; 3.1%)
Head and neck 494 12
Trunk 1746 42.4
Upper extremities 1261 30.6
Lower extremities 615 14.9
Breslow thickness
Median 0.6
p75‐p25 0.4‐0.8
<0.8 3018 71
0.8‐1.0 1231 29
Ulceration (missing = 495; 11.6%)
Absent 3613 96.2
Present 141 3.8
Mitotic rate (missing = 1752; 41.2%)
0 mitoses/mm2 1674 67
1 mitosis/mm2 514 20.6
2 mitoses/mm2 176 7
>2 mitoses/mm2 133 5.3
Histologic subtypes (missing = 64; 1.5%)
LMM 346 8.3
SSM 3487 83.3
NM 89 2.1
ALM 94 2.2
Other 169 4
Clark level (missing = 973; 22.9%)
II‐III 2838 86.6
IV‐V 438 13.4
Lymphovascular invasion (missing = 1887; 
44.4%)
Absent 2287 99.3
Present 15 0.4
Regression (missing = 848; 20%)
Absent 2175 64
Present 1226 36
(Continues)
Characteristic No. %
Hospital
1 130 3.1
2 698 16.4
3 984 23.2
4 1210 28.5
5 505 11.9
6 80 1.9
7 284 6.7
8 247 5.8
9 109 2.6
Notes: Hospital: 1. Hospital Universitario de Salamanca (Salamanca, 
Spain); 2. Instituto Valenciano de Oncología (Valencia, Spain); 3. Hospital 
Clìnic (Barcelona, Spain); 4. Hospital de Turin (Turin, Italy); 5. Hospital 
German Trials i Pujol (Badalona, Spain); 6. Hospital de Coimbra (Coimbra, 
Portugal); 7. Hospital Universitario A Coruña (A Coruña, Spain); 8. 
Hospital Virgen Macarena (Seville, Spain); 9. Hospital La Fe (Valencia, 
Spain).
Abbreviations: ALM, acral lentiginous melanoma; LMM, lentigo maligna mela-
noma; NM, nodular melanoma; SSM, superficial spreading melanoma.
T A B L E  1  (Continued)
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significantly associated with DFI and MMS (Table 2). On an-
alyzing SNLB patients only (n = 1083), SLN status was the 
most important prognostic factor for both DFI (hazard ratio 
7.4; 95% CI, 4.1‐13.5) (P < 0.001) and MSS (hazard ratio, 
12.8; 95% CI 5.4‐30.2) (P < 0.001). Additional independent 
predictors of DFI and MSS were sex, age, Clark level, and 
ulceration (Table 2).
The cumulative estimated survival rates for T1a mel-
anoma patients at 5, 10, and 15  years, respectively, were 
97.6%, 96.1%, 93.2% for DFI, and 99.5%, 98.5%, and 97.2% 
for MSS (Figure 1A and 1B) (P < 0.001). The corresponding 
rates for patients with T1b melanoma were 93.3%, 88.5%, 
and 80.8% for DFI and 96.3%, 94.8%, and 88.6% for MSS 
(Figure 1A and 1B) (P < 0.001).
The characteristics of the patients who underwent SLNB 
are summarized by SLN status in Table 1. Of the 1083 pa-
tients with thin melanoma who underwent SLNB, 73 (6.7%) 
had a positive result. The median of positive SLNB patients 
was higher than negative SLNB (0.9 vs 0.8  mm). Only 
Breslow thickness (odd ratio [OR] 1.7 [95% CI, 1‐2.92]; 
P = 0.05) and mitotic rate (>2 mitoses/mm2) (OR, 3.4 [95% 
CI, 1.5‐7.7]; P = 0.003) were associated with a positive sta-
tus in the univariate analysis. In the multivariate analysis, 
only mitotic rate retained its prognostic significance (OR, 
2.9 [95% CI, 1.22‐7]; P = 0.01) (Table 3).
The frequency of positive SLNB results for each com-
bination of mitotic rate and clinical stage (T1a vs T1b) was 
evaluated according to the different recommendations and 
T A B L E  2  Multivariate Cox regression model for disease‐free 
interval and melanoma‐specific survival in the entire cohort and in 
patients who underwent sentinel lymph node biopsy
Variable
Hazard 
ratio 95% CI P value
Entire cohort (n = 4249)
Disease‐free interval
Sex (female vs male) 0.7 0.5‐0.8 0.006
Ulceration (presence vs 
absence)
2.4 1.3‐4.3 0.006
Others vs LMM 0.3 0.2‐0.9 0.031
≥0.8 mm vs <0.8 mm 
Breslow thickness
1.6 1.1‐3 0.01
Clark level (IV‐V vs II‐III) 3.1 2‐4.8 <0.001
Melanoma‐specific survival
Sex (female vs male) 0.4 0.2‐0.7 <0.001
Ulceration (presence vs 
absence)
2.9 1.4‐6.1 0.005
ALM vs LMM 15.1 2.3‐98.6 0.004
≥0.8 mm vs <0.8 mm 
Breslow
1.9 1.1‐3.2 0.021
Clark level (IV‐V vs II‐III) 3 1.6‐5.7 0.001
Patients underwent SLNB 
(n = 1090)
Disease‐free interval
Sex (female vs male) 0.5 0.3‐0.9 0.027
Age >5 vs <40 2.5 1.1‐5.7 0.028
Ulceration (presence vs 
absence)
3 1.5‐5.9 0.002
Clark level (IV‐V vs II‐III) 2.8 1.6‐4.9 <0.001
SLNB (positive vs negative) 7.4 4.1‐13.5 <0.001
Melanoma‐specific survival
Sex (female vs male) 0.3 0.1‐0.6 0.004
Age >65 vs <40 3.5 1‐12.1 0.044
Ulceration (presence vs 
absence)
4.3 1.7‐10.4 0.001
Clark level (IV‐V vs II‐III) 2.6 1.1‐6.1 0.022
SLNB (positive vs negative) 12.8 5.4‐30.2 <0.001
Abbreviations: ALM, acral lentiginous melanoma; LMM, lentigo maligna mela-
noma; NM, nodular melanoma; SSM, superficial spreading melanoma; SLNB: 
Sentinel lymph node biopsy.
F I G U R E  1  Kaplan‐Meier disease‐specific survival curves for 
patients with thin melanoma according to the staging criteria of the 8th 
edition of the American Joint Committee on Cancer Staging Manual, 
T1a vs T1b
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criteria described in the NCCN and ASCO‐SSO guidelines 
(Table 4). Patients with T1a melanoma had an SLN positiv-
ity rate of 3.4% and this rose to 20% in those with ≥2 mitosis/
mm2. The overall SLN positivity rate in patients with T1b 
melanoma was 8%, but this fell to 3.6% in the subgroup of 
patients with 0 mitosis/mm2. Based on the NCCN recom-
mendations for stage T1a thin melanoma with ≥2 mitosis/
mm2, the SLN positivity rate was 7.8%. None of the 17 pa-
tients in the younger age group (<40 years) had a positive 
SLNB. We were unable to evaluate the frequency of positive 
Independent variable
Univariate analysis Multivariate analysis
P value
Odds ratio (95% 
CI) P value
Odds ratio 
(95% CI)
Sex
Female 1 —
Male 0.21 0.74 (0.52‐1.21) — —
Age, y
<40 1
40‐65 0.25 0.72 (0.41‐1.26) — —
>65 0.78 0.91 (0.47‐1.75) — —
Anatomic location
Head/neck 1 —
Trunk 0.89 1.06 (0.43‐2.59) — —
Upper extremities 0.57 0.75 (0.29‐1.96) — —
Lower extremities 0.73 0.84 (0.30‐2.32) — —
Breslow thickness
<0.8 mm 1
0.8‐1 mm 0.05 1.7 (1‐2.92) — —
Ulceration
Present 0.6 1.22 (0.61‐1.63) — —
Absent 1
Mitosis rate
0 mitoses/mm2 1 1
1 mitosis/mm2 0.5 1.3 (0.6‐2.9) 0.5 1.3 
(0.6‐2.9)
2 mitoses/mm2 0.06 2.23 (0.97‐5.14) 0.08 2.1 
(0.9‐4.95)
>2 mitoses/mm2 0.003 3.42 (1.52‐7.73) 0.01 2.9 (1.22‐7)
Regression
Present 1 —
Absent 0.39 1.27 (0.73‐2.19) — —
Clark level
II‐III 1 —
IV‐V 0.18 1.41 (0.84‐2.37) — —
Histologic subtype
LMM 1 —
SSM 0.61 1.44 (0.31‐6.13) — —
NM 0.34 2.22 (0.42‐11.7) — —
Others 0.47 0.48 (0.06‐3.46) — —
Lymphovascular invasion
Present 0.71 1.44 (0.19‐10.9) — —
Absent 1
T A B L E  3  Univariate and multivariate 
analysis of predictive factors for positive 
sentinel lymph node biopsy in 1090 patients 
with thin melanoma
   | 4241TEJERA‐VAQUERIZO ET Al.
SLNB results in patients with lymphovascular invasion, as 
there were just three cases.
Over a median follow‐up of 64 months for patients in 
the SLNB subgroup, 58 patients experienced disease re-
currence (locoregional 26.3%, regional 19.3%, and distant 
54.5%) and 30 died of melanoma. DFI at 5 and 10 years 
was, respectively, 96.5% and 94.1% for SLN‐negative 
patients and 72.2% and 64.5% for SLN‐positive patients 
(P < 0.001)(Figure 2A). Five‐and 10‐year MSS, by con-
trast, was 98.7% and 97.6% for SLN‐negative patients and 
83.8% and 74.3% for SLN‐positive patients (P  <  0.001) 
(Figure 2B).
The number of false negative patients was nine. The false 
negative rate was 10.8%. This was calculated by dividing the 
number of false negatives by the sum of false negatives plus 
true positives following van Akkooi's method.14
4 |  DISCUSSION
This study shows that SLN status is the most important 
prognostic factor in thin melanoma. Coinciding with the re-
vised AJCC staging system,3 the most important factors for 
MSS, not counting SLN status, were Breslow thickness and 
ulceration, followed by sex, Clark level, and acral lentiginous 
melanoma.
It is noteworthy that 5‐year MSS of positive SLNB patient 
is worse in our study with respect to other similar studies.15,16 
It is probably due to a difference in the selection of patients 
who underwent the SLNB.
Female sex confers a survival benefit in thin melanoma. 
Although this benefit is widely recognized,17,18 no logical ex-
planation has yet been found.
The findings of our study support a prognostic role for 
Clark level in thin melanoma. Clark level, defined by Wallace 
Clark,19 was considered a prognostic factor in thin melanoma 
in earlier editions of the AJCC Cancer Staging Manual, but it 
was replaced by mitogenicity in the 6th edition.20 Clark level 
is less reproducible than tumor thickness for pathologists as its 
interpretation is limited by differences between the papillary 
and reticular dermis in patients with solar elastosis or in certain 
areas, such as the scalp, acral sites, and mucosal membranes.
Acral lentiginous melanoma is a subtype of melanoma 
defined by the World Health Organization.21 The Clark clas-
sification of melanomas, which is based on different epide-
miological and genetic features, is not free of criticism due 
to the overlapping of the histopathologic criteria on which it 
is based.22
T A B L E  4  Association between SLN status and different tumor staging criteria for thin melanoma within the framework of current guideline 
recommendations for SLN biopsy
Scenario All patients
SLN positivity 
n (%) NCCN guidelines ASCO‐SSO guideline Present study
T1a (NCCN)
≥2 mitoses/mm2 51 4 (7.8) DC NR DC
Lymphovascular 
invasion
3 0 (0) DC NR ** 
≥2 mitoses/mm2 + 
young agea
17 0 (0) DC NR NR
T1a (present study)
All 358 12 (3.4) NR NR NR
0 mitoses/mm2 84 1 (1.2) NR NR NR
1 mitosis/mm2 121 3 (2.5) NR NR NR
2 mitoses/mm2 36 1 (2.8) DC NR NR
>2 mitoses/mm2 15 3 (20) DC NR DC
T1b (present study)
All 713 57 (8) DC DC DC
0 mitoses/mm2 168 6 (3.6) DC DC NR
1 mitosis/mm2 164 11 (6.7) DC DC DC
2 mitoses/mm2 80 11 (13.8) DC DC DC
>2 mitoses/mm2 68 9 (13.2) DC DC DC
Abbreviations: DC, discuss and consider; NR: not recommended; SLN, sentinel lymph node.
a<45 years old. 
**Insufficient number. 
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Several reasons for the worse prognosis associated with 
acral lentiginous melanoma have been postulated, including 
differences in mutations and amplifications, such as a lower 
incidence of BRAF/NRAS mutations,20 a higher incidence of 
KIT mutations or amplifications,23 and amplification of the 
TERT gene24 in melanomas classified using the Clark system.
Although SLN status has been identified as the most im-
portant prognostic factor in thin melanoma,16,25 there is no 
consensus on which patients should be offered SLNB. The 
updated ASCO‐SSO guideline does not recommend SLNB 
for T1a melanomas.9 Version 1.2018 of the NCCN mela-
noma guidelines, however, which incorporate the AJCC's 
latest modifications to the staging criteria for thin mela-
noma,8 recommend the procedure if the risk of a positive 
SLN is more than 5%. In the specific case of thin melanoma, 
it recommends considering SLNB in patients with “T1a le-
sions <0.8 mm with other adverse features (eg. very high mi-
totic index ≥2/mm2 [particularly in the setting of young age], 
lymphovascular invasion, or a combination of these factors).” 
This recommendation, however, is not supported by clinical 
studies.
Our findings support the indication for SLNB in pa-
tients with T1a melanoma and a high mitotic rate (>2/
mm2). We found no significant associations with patient age. 
Lymphovascular invasion was not included in the regression 
model as it was only identified in 15 patients and none of 
them had SLN metastasis.
Another noteworthy finding in our study was the low rate 
of SLN positivity (just 3.6%) in patients with T1b melanoma 
without mitosis. In a recent study of 203 cases of thin mel-
anoma, a similarly low rate was reported for patients with 
T1b melanoma without mitoses or with a low mitotic rate.12 
Bartlett et al,26 in a study of 781 patients with thin melanoma 
who underwent SLNB, also found absence of mitotic activity 
to be associated with a low probability of SLN metastasis, 
even in patients with thin melanomas >0.75 mm. Although 
the ASCO‐SSO and NCCN clinical practice guidelines rec-
ommend SLNB for patients with T1b melanoma, perhaps the 
option of not performing the procedure should be contem-
plated in patients without mitoses.
Previous studies have not found significant associations 
between mitotic rate and SLN status in thin melanoma,27-29 
but this is probably because they analyzed small samples 
or used different cutoff points.16 Han et al15 is one of the 
most numerous studies, did not find any factor related to at 
least 5% of possibility to have a positive SLN in melano-
mas  <0.75  mm in dept. In a recent study of thin melano-
mas from the US National Cancer Database, Wheless et al30 
observed a positive linear relationship between mitotic rate 
and increased odds of SLN involvement. A greater likelihood 
of SLN metastasis in the presence of dermal mitoses in thin 
melanoma has also been reported elsewhere.31,32 Unlike us, 
however, the authors did not quantify the number of mitoses.
Our study has some limitations, including its retrospec-
tive design and the fact that data were missing for some 
variables. Information on mitotic rate, for example, was 
missing for 41.2% of patients. On analyzing the differences 
between patients with and without data on mitotic rate, we 
found no differences for Breslow thickness or ulceration 
(data not shown). Another possible limitation of our study 
is that it was performed in southern Europe, where there is 
a low incidence of melanoma compared with other areas 
of the continent. The SLN positivity rate for patients with 
thin melanoma in our study was 6.7%, but on counting the 
false negatives, it was 7.5%, which is higher than in other 
series.26 It can be assumed, however, that this higher rate 
did not affect the aim of the study. Our study also has im-
portant strengths, such as its multicenter design and the 
large number of patients analyzed. Finally, the adequacy of 
the follow‐up period is assured by the similarities observed 
between the survival rates in our study and those reported 
by the AJCC for thin melanoma.
F I G U R E  2  Kaplan‐Meier survival curves for patients with thin 
melanoma according to sentinel lymph node status: (A) Disease‐free 
interval; (B) Melanoma‐specific survival
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5 |  CONCLUSIONS
SLN involvement is the most important prognostic factor 
among patients undergoing SLNB in thin melanoma. High 
mitotic rate is associated with SLN metastasis but probably 
has no impact on survival in patients with thin melanoma. 
SLNB should be recommended in patients with T1a mela-
noma and a high mitotic rate, as even though this combina-
tion is uncommon, it is associated with a high risk of SLN 
metastasis. Sex, acral lentiginous melanoma, and Clark level 
were also independently associated with survival in our co-
hort and should be taken into account when devising new 
staging systems. More studies, however, are needed to vali-
date our findings.
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